Skip to content
drillr.ai
Sign up

300841.SZ

康华生物

SZSE · Healthcare · C 制造业 · CN

CNY 53.27
−5.72%
Ask drillr

  • Aug 17, 2026, 10:38 UTC

    Kanghua Biological announced its first-half 2026 results: revenue of 538 million yuan, up 11.25% year-on-year; net profit attributable to shareholders of 141 million yuan, up 23.25% year-on-year; non-recurring-adjusted net profit of 134 million yuan, up 20.28% year-on-year. The company plans no cash dividend, no bonus shares, and no capital reserve conversion.

    Source:

  • Aug 3, 2026, 10:02 UTC

    Kanghua Biotech announced that its external investment and related-party transaction proposal was approved at an extraordinary shareholders' meeting, planning to subscribe in installments to Namixin's newly increased registered capital and acquire equity, holding 100% of Namixin after completion; recently Namixin completed the first-phase industrial and commercial change registration with a registered capital of 27.17 million yuan.

    Source: